CTC
IART icon

Central Trust Company’s Integra LifeSciences IART Stock Holding History

Central Trust Company’s Portfolio IART Stock Details IART Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-220
Closed -$13K – 1170
2019
Q4 		$13K Sell
220
-105
-32% -$6.25K ﹤0.01% 908
2019
Q3 		$20K Buy
+325
New +$19.4K ﹤0.01% 794
2017
Q4 		– Sell
-84
Closed -$4K – 1310
2017
Q3 		$4K Buy
+84
New +$4.31K ﹤0.01% 1074

Other funds holding IART

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CIP
Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
CB
Cooke & Bieler Philadelphia, Pennsylvania $8.84B AUM 6.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Central Trust Company's IART Position: Q1 2020 in Review

Central Trust Company sold out of Integra LifeSciences (IART) in Q1 2020, closing a stake of 220 shares — an estimated $13K sold.

Central Trust Company first reported a position in IART in Q3 2017 and held it in 3 quarters. The position peaked at $20K in Q3 2019. 258 funds tracked by Wall St. Rank hold IART as of Q1 2020.

  • Central Trust Company reported no remaining Integra LifeSciences position as of Q1 2020 after selling out during the quarter.
  • Central Trust Company sold 220 Integra LifeSciences shares in Q1 2020, an estimated $13K.
  • Central Trust Company first reported a position in Integra LifeSciences in Q3 2017 and held it in 3 quarters.
  • Central Trust Company's Integra LifeSciences position peaked at $20K in Q3 2019.
  • 258 funds tracked by Wall St. Rank held Integra LifeSciences as of Q1 2020.

Based on Central Trust Company's 13F filing for Q1 2020, filed 17 Apr 2020.